Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Vaslin

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Molecular Medicine (Cambridge, Mass.)|October 27, 2004
Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activationCsaba Szabó, Pál Pacher, Zsuzsanna Zsengellér, et al.
The Journal of Biological Chemistry|February 26, 2009
Calpain hydrolysis of alpha- and beta2-adaptins decreases clathrin-dependent endocytosis and may promote neurodegenerationNikita Rudinskiy, Yulia Grishchuk, Anne Vaslin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2005
Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activationJon G Mabley, Eszter M Horváth, Kanneganti G K Murthy, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 24, 2004
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced agingPál Pacher, Anne Vaslin, Rita Benko, et al.
Contrast Media & Molecular Imaging|January 11, 2019
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer ModelPierre-Simon Bellaye, Alexandra Oudot, Jean-Marc Vrigneaud, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 17, 2008
Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligandFrancesc X Soriano, Marc-Andre Martel, Sofia Papadia, et al.
Molecular Cancer Therapeutics|May 5, 2017
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34<sup>+</sup> Stem/Progenitor CellsMaximilien Murone, Ramin Radpour, Antoine Attinger, et al.
Molecular Cancer Therapeutics|July 22, 2016
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine KinasesMaximilien Murone, Anne Vaslin Chessex, Antoine Attinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene AlterationsMartin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Molecular Medicine (Cambridge, Mass.)|October 27, 2004
Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activationCsaba Szabó, Pál Pacher, Zsuzsanna Zsengellér, et al.
The Journal of Biological Chemistry|February 26, 2009
Calpain hydrolysis of alpha- and beta2-adaptins decreases clathrin-dependent endocytosis and may promote neurodegenerationNikita Rudinskiy, Yulia Grishchuk, Anne Vaslin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2005
Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activationJon G Mabley, Eszter M Horváth, Kanneganti G K Murthy, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 24, 2004
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced agingPál Pacher, Anne Vaslin, Rita Benko, et al.
Contrast Media & Molecular Imaging|January 11, 2019
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer ModelPierre-Simon Bellaye, Alexandra Oudot, Jean-Marc Vrigneaud, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 17, 2008
Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligandFrancesc X Soriano, Marc-Andre Martel, Sofia Papadia, et al.
Molecular Cancer Therapeutics|May 5, 2017
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34<sup>+</sup> Stem/Progenitor CellsMaximilien Murone, Ramin Radpour, Antoine Attinger, et al.
Molecular Cancer Therapeutics|July 22, 2016
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine KinasesMaximilien Murone, Anne Vaslin Chessex, Antoine Attinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene AlterationsMartin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Pageof 3